Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking with respect to its effects on cardiovascular outcomes. METHODS In this international, double-blind, randomized, placebo-controlled trial, we randomly assigned, in a 1:1 ratio, 731 patients with heart failure, an ejection fraction of at least 50%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 30 to receive tirzepatide (up to 15 mg subcutaneously once per week) or placebo for at least 52 weeks. The two primary end points were a composite of adjudicated death from cardiovascular causes or a worsening heart-failure event (assessed in a time-to-first-event analysis) and the change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better quality of life). RESULTS A total of 364 patients were assigned to the tirzepatide group and 367 to the placebo group; the median duration of follow-up was 104 weeks. Adjudicated death from cardiovascular causes or a worsening heart-failure event occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the SUMMIT trial (for tirzepatide) showed a reduction in events regarding time to cardiovascular death or worsening heart failure over 104 weeks (HR 0•62, 0•41-0•95), 79”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [79]
In the citing paper
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [30]
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“Tirzepatide also lowers CRP levels in clinical trials in people with heart failure with preserved ejection fraction, or OSA (19, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“In the SUMMIT trial (Study of Tirzepatide in Participants With Heart Failure With Preserved Ejection Fraction and Obesity), tirzepatide reduced the risk of the composite of cardiovascular death and worsening HF events.23”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [23]
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Self-citationSemaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313917 · Cited by 758
Self-citationPacker, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.509 · Cited by 656
Self-citationTirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541
The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF
Savji, N., Meijers, W. C., Bartz, T. M., Bhambhani, V., Cushman, M., Nayor, M., Kizer, J. R., Sarma, A., Blaha, M. J., Gansevoort, R. T., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.05.018 · Cited by 499
Borlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac120 · Cited by 450
Self-citationPaulus, W. J., & Zile, M. R. (2021) · Circulation Research · doi:10.1161/circresaha.121.318159 · Cited by 393
Self-citationKosiborod, M. N., Deanfield, J., Pratley, R., Borlaug, B. A., Butler, J., Davies, M. J., Emerson, S. S., Kahn, S. E., Kitzman, D. W., Lingvay, I., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01643-x · Cited by 308
Self-citation
Cited by
Items 901–1,000 of 1,086
Khalil, I., Hossain, M. I., Akter, M. M., Wahid, F., Khalid, A. A., Promi, S. A., Sayed, M. A., Rahman, M. T., & Sarker, P. (2026) · Clinical Cardiology · doi:10.1002/clc.70441
ПЛЕЙОТРОПНЫЕ ЭФФЕКТЫ АГОНИСТОВ РЕЦЕПТОРОВ ГЛЮКАГОНОПОДОБНОГО ПЕПТИДА‑1
Юрьевич, Ц. В., Lazareva, I. A., Владимировна, Б. Н., Полякова, О. В., & Николаевна, У. С. (2026) · Современные проблемы науки и образования · doi:10.17513/spno.34690
Hobai, I. A., & Goodin, B. (2026) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000008227
Cardiovascular Prevention and the Implementation Gap in GLP-1 Receptor Agonist Therapies
Erhabor, J., Silver, N., & Blaha, M. J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.06.024
Dagan, M., Nanayakkara, S., Beale, A. L., Komtebedde, J., Mylavarapu, U., Hasenfuβ, G., Litwin, S. E., Mohan, R. C., Gorter, T. M., Čikeš, M., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag210
“Although the magnitude of weight loss achieved with SGLT2 inhibition is modest compared to incretin-based therapies, 4,16 reductions in body weight are consistently observed, with greater effects amongst those with higher baseline BMI.”
Self-citationGoshe, M., Singh, S., Zameer, R., Ali, J., Kumari, N., & Das, M. (2026) · Cureus · doi:10.7759/cureus.114404
“Landmark trials such as EMPEROR-Preserved [16] and SUMMIT [17] have strengthened this evidence beyond ejection fraction-based classification by demonstrating therapeutic benefit in broad HFpEF and obesity-related HFpEF populations, respectively.”
Neto, T. F., Cunha, B. Z., do Nascimento, M. B. D. M. T., Medeiros, B. C., Filho, G. M., da Silva, M. P., Lambertini, G. J. G., de Souza, D. A., & Vivan, J. B. (2026) · Asclepius International Journal of Scientific Health Science · doi:10.70779/aijshs.v5i8.655
Alhazmi, A. M., Alayoubi, F., Mufti, R. E., & Albulushi, A. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103423
Chaparro, S. V., & Rivera-Rodríguez, M. (2026) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_192-2
Khidhir, A., & Kalra, D. K. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01451-x
Cheng, X., Ma, R., Guo, M., Wei, J., Zhao, Q., Yu, R. E., Dong, Z., Wang, J., Wang, Y., 朱明军, et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1902637
Kamal, M. (2026) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2026.101977
Ming, Q., & Li, Z. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1914155
“…of Tirzepatide in Participants With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT) further raised expectations: tirzepatide reduced the composite of cardiovascular death or worsening HF while improving health status, body weight, and walking capacity in HFpEF with obesity (16).”
Canecki-Varžić, S., Bilić-Čurčić, I., Bakula, M., Bulum, T., Naglić, M. Č., Delić-Brkljačić, D., Wensveen, T. T., Vitković, D. F., Jurišić‐Eržen, D., Klobučar, S., et al. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1834323 · Cited by 1
Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis
Chen, Q.-X., Xiao-yu, Z., Wu, Q., Xie, J.-J., Xu, Y., Teng, F., & Guo, M. (2026) · Endocrine · doi:10.1007/s12020-026-04757-7 · Cited by 1
“…of up to about 20.9% in SUR-MOUNT-1 [ 29 ] and has shown benefits in patients with heart failure with preserved ejection fraction in SUMMIT [ 41 ]; in our meta-analysis, it was associated with a lower risk of hypertension-related TEAEs (RR = 0.40) but a higher risk of hypotension-related…”
InfluentialMortada, I., Lee, A. W., Buckingham, D., Quach, V., Rice, J., Mansour, S., Chatila, K., Shalaby, M., Jehle, D. V., Boyars, M. C., et al. (2026) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/17539447261478928
“14 Although sex-specific outcomes were not a primary focus of that study, the overall cardiometabolic benefits observed were consistent across diverse patient subgroups.”
Grewal, U. S., Ear, P. H., Sonbol, M. B., Bellizzi, A. M., Hofland, J., Crona, J., Dillon, J. S., Chan, J. A., Howe, J. R., Strosberg, J., et al. (2026) · Cancer · doi:10.1002/cncr.70586
Mazzone, P. M., Giacoppo, D., Ammirabile, N., Mauro, M. S., Spagna, F., & Capodanno, D. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag430
He, W., Yi-di, S., Wang, X., He, S.-Y., Tao, X., Yuan, S.-X., Zhou, L., & Long, E.-W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1889594
Luo, W., Zuo, W., Xu, Y., Yang, M., Ji, Z., & Ma, G. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108403
Moradi, A., Ramey, K., Tabbaa, K., Sahyouni, A., Garcez, K. S., KUMAR, S., Pan, E. H., Barton, G., Oyesanmi, O., & Subbiondo, R. J. (2026) · Pathophysiology · doi:10.3390/pathophysiology33030063
“The SUM-MIT trial subsequently demonstrated that tirzepatide reduced the risk of the composite of cardiovascular death or worsening heart failure and improved health status and exercise capacity in patients with HFpEF and obesity [69].”
Yu, F.-C., Wu, C., Sung, S., Wu, Y., Hsiao, C., Chang, K.-C., Tzeng, B., Tsai, C., & Hung, C. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.08.032
Evolving indications for metabolic and bariatric surgery
Wills, M. V., & Corcelles, R. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.06.009
Almahmeed, W. A., Barajas-Gamboa, J. S., Zubaid, M., Al‐Ozairi, E., Shehab, A., Al‐Rasadi, K., Khalil, C. A., Busaidi, N. A., Sindi, F. A., Awan, Z. A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70204
Corrado, R., Raffa, S. D., Bauer, E. M., Eisenberg, D., Weare-Regales, N., Antonovich, N., Loblack, A., Berdiel, E., Kelber, M. S., Klimovich, J., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-00676
Zhao, Y., Zhang, H., Li, J., & Wang, F. (2026) · Research Square · doi:10.21203/rs.3.rs-10549910/v1
Gong, B., Xu, H., Liu, H., Wang, M., Yang, K., Chen, J., Guo, X., Zhang, T., & Ge, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1924339 · Cited by 1
“Tirzepatide reduced the composite risk of cardiovascular death or worsening heart failure, improved health status, and lowered hs-CRP at 52 weeks (149).”
Thapa, K., Verrou, K., Rapushi, E., Siokatas, G., Krishnan, K. C., Bharucha, N., Keating, B. J., Meyer, M., Karakikes, I., & Drosatos, K. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.20.746109
Update on the classification and treatment approaches for heart failure in 2026
Skybchyk, V. А., & О.П., Т. (2026) · Medicine of Ukraine · doi:10.37987/1997-9894.2026.5(301).367141
Artificial intelligence and heart failure guidelines: prediction or judgement?
Khan, M. S., Coats, A. J. S., Cushman, S., Colardelle, Y., & Anker, S. D. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag278
From risk marker to treatment trigger: biomarker-guided decision-making in acute heart failurePreprint
Sosnov, M., & Seleznova, M. (2026) · Research Square · doi:10.21203/rs.3.rs-10629275/v1
Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception
Koca, N., Uyar, S., Şahintürk, Y., Yıldız, H., Prato, S. D., & DeFronzo, R. A. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03346-2
“Improved outcomes in heart failure with preserved ejection fraction [23] and favorable effects on steatohepatitis [24] have also been reported for tirzepatide.”
Chabalout, M. N., Alazzeh, M., Othman, D., & Virk, J. P. S. (2026) · Cureus · doi:10.7759/cureus.115294
Seth, S., Chopra, V., Sinha, N., Nair, T., Böhm, M., Sawhney, J. P. S., Oomman, A., Jaswal, A., Gopi, A., Rao, S., et al. (2026) · Journal of the Practice of Cardiovascular Sciences · doi:10.4103/jpcs.jpcs_64_26
Yan, Z., Pu, X., Ren, T., Cai, Y., Xu, Y., Chen, J., Chang, X., Wang, Y., Liu, Z., & Liu, R. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07941-z
Metabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting
Cheng, C., Tang, M., 张兆波, Qu, R., Pei, J., Liu, T., Qu, S., You, S., Cui, S., Wang, W., et al. (2026) · Advanced Science · doi:10.1002/advs.77260 · Cited by 1
“In HFpEF with obesity, semaglu-tide improves symptoms and reduces inflammation [ 162, 180 ], and tirzepatide reduces heart failure events [ 163 ].”
From adiposity to multisystem morbidity: the case for weight loss as disease modification
Sattar, N. A., Ferguson, L. D., & Lee, M. M. Y. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00186-5
Oral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine
Guo, J., & Chen, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1933018
Smith, C. R. (2026) · Considerations in Medicine · doi:10.1136/conmed-2026-000055
Ripoll, J. G., Herrera, H. R., Zaremba, S., Maruniak, S. R., Ursoleo, J. D., Wieruszewski, P. M., & Ramakrishna, H. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.08.160
Technology and Obesity: A Year in Review
Patra, S., Bhandarkar, A. P., Kapoor, N., & Kalra, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03775-1
Management of Obesity: Review of Adjunctive Therapies and Clinical Management Pearls
Sullivan, S. A., Tavakkoli, A., & Butsch, W. S. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.08.017
Damasio, N. M. A., Freccia, G. W., Fortes, M. D. S. R., Gomes, M. G. Z., & de Lira, C. A. B. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100743
Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-026-00131-3
Great debate: diabetic cardiomyopathy is a distinct disease
Seferovic, P. M., Marx, N., Polovina, M. M., Prato, S. D., Chioncel, O. D., Balfanz, P., Dérumeaux, G., Schuett, K. A., & Bauersachs, J. K. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag606
Defining Clinically Meaningful Within-Patient Changes in Heart Failure
Yehya, A., Hahn, R. T., Borlaug, B., Delgado, V., Ambrosy, A. P., Arena, R. A., Reza, N., Lewis, G. D., Tapaskar, N., Carbone, S., et al. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103310 · Cited by 1
Self-citationGLP-1/GIP Uptake, Indication, and Access Pathways Among US Adults in the Understanding America StudyPreprint
Chaturvedi, R. R., Gračner, T., Pérez‐Arce, F., Suen, S., Jin, J., Orriens, B., Pacula, R. L., Ward, A. S., Haile, R., & Kapteyn, A. (2026) · medRxiv · doi:10.64898/2026.08.28.26361368
Lee, C.-M., Kim, J.-Y., Shim, J.-H., & Cho, G.-W. (2026) · Hormone and Metabolic Research · doi:10.1055/a-2928-5204
Body Composition in Heart Failure: A Phenotype-Informed Framework for Assessment and Management
van der Hoef, C. C. S., ter Maaten, J. M., Meems, L. M. G., Gorter, T. M., Tromp, J., van Veldhuisen, D. J., & Voors, A. A. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.08.018
The Evolution of Medications for Obesity Management
Gill, J., & Sumithran, P. (2026) · JGH Open · doi:10.1002/jgh3.70466
“Both semaglutide 2.4 mg weekly and tirzepatide have demonstrated improvements in symptoms, quality of life, and physical function in people with overweight/obesity and heart failure with preserved ejection fraction (HFpEF) [67, 68].”
InfluentialAhmed, M. (2025) · Journal of Prevention Diagnosis and Management of Human Diseases · doi:10.55529/jpdmhd.52.68.79
Obesity in Heart Failure: Mechanistic, Diagnostic and Therapeutic Considerations
Pathan, F. K., & Williams, K. (2026) · Cardiac failure review · doi:10.15420/cfr.2026.05
“53 There are no randomised trials evaluating the impact of bariatric surgery in patients with obesity and HFpEF.”
Ahmed, M. (2025) · Journal of Prevention Diagnosis and Management of Human Diseases · doi:10.55529/jpdmhd.52.95.108
Karanxha, J., Guni, M., Xhabija, N., Dede, M., Mone, I., & Prifti, E. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134773
Glp-1 receptor agonists in obesity: Current evidence and clinical outcomes
Vidal, J. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.08.009
AlAraibi, A. J., Shakeeb, F. N., Alqatta, T., Sharafeldin, A.-B. K., Dempsey, L., & Butler, A. E. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104994
Queiroz, N. K. N., Gomes, J. C., de Faria, R. M., Leite, H. L., da Cruz, L. C., Neto, T. F., de Caballero, T. G. G., & Rodrigues, L. T. (2026) · Asclepius International Journal of Scientific Health Science · doi:10.70779/aijshs.v5i9.676
Jastreboff, A. M., Ard, J. D., Hall, K. D., Kaplan, L. M., Krumholz, H. M., Name, M. A. V., Ryan, D. H., & Drucker, D. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag025 · Cited by 1
“…a median of 104 weeks, tirzepatide (up to 15 mg weekly) reduced the composite of cardiovascular death or worsening heart failure by 38% (HR, 0.62; 95% CI, 0.41-0.95; 9.9% vs 15.3%), driven principally by fewer worsening heart failure events and accompanied by symptomatic and functional gains (204).”
InfluentialMansouri, E. S., de Queiroga, F. F., Barbosa, L., Azevedo, A. K., Donaldy, W., Mirbolouk, M. J., Freire, C. V. S., Rivera, A., Félix, I. F., Abreu, M., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.044249 · Cited by 1
Hegazy, M., Soliman, S., Ahmed, M., Attia, A., Bellakhal, S., Tawfik, N. M., & Soliman, A. R. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02408-x
“…walk distance; cardiac mag - netic resonance substudy findings of reduced left ventricu - lar mass and paracardiac adipose tissue directly implicate improvements in visceral adiposity and cardiac mechanics, mechanisms that are intimately linked to hepatic steatosis and systemic inflammation [43 ].”
Chattha, S. S., Kapadia, K., Lynch, D., & McWhorter, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1812235
Chirapongsathorn, S., & Tacke, F. (2026) · Digestion · doi:10.1159/dig/acmag014
Cardiovascular effects of incretin receptor agonists: beyond glycemic control
Ravić, M. P., Srejovic, I. M., Milosavljević, I., Novakovic, J. N., Jakovljević, V., Vučićević, K., Petrovic, D., & Muric, M. D. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2026-0184
ADVANCES IN OBESITY PHARMACOTHERAPY: CURRENT STATE AND FUTURE PERSPECTIVES
Wielogórska, A., Stasiak, O., Kowalik, F., & Deczkowska, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5972
Dodin, B. E., Sodhi, P., Konz, M. G., Hess, T., & Wright, J. M. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.09.008
Combination of genetic eNOS deficiency and high-fat diet induces reproducible cardiometabolic HFpEF
Elbatreek, M. H., Khodade, V. S., Amin, D., Huerta, M., Allerton, T. D., Polhemus, D. J., Shah, S. J., Vondriska, T. M., Goodchild, T. T., & Lefer, D. J. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104394
“To determine the translational utility of this genetic-metabolic model, we evaluated its responsiveness to a clinically relevant pharmacological intervention that has previously been shown to be effective in cardiometabolic HFpEF in the clinic [15 – 19].”
Skeletal Muscle Dysfunction in Heart Failure
Challa, A. A., Pandey, A., Brubaker, P. H., Kitzman, D. W., Bozkurt, B., & Kalra, D. K. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103353
Stoichescu-Hogea, G., Craciun, M.-L., Pah, A.-M., Avram, A. C., Rada, M., Otiman, G., Jupaneant, C., Ples, C., Mahmoud, A., & Dragan, S. R. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187096 · Cited by 1
“…adjudicated obesity-related HFpEF populations shows that exercise, caloric restriction, semaglutide, and tirzepatide can improve selected clinical outcomes [20–24], but these trials neither validate HFpEF in the present cohort nor convert a cross-sectional BMI association into a treatment effect.”
The Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care
Wojeck, B. S., & Nokes, B. T. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101038
Allaham, L., King, B. J., Ali, F., GUPTA, I., Metuku, R., Nieto, I., Lurie, A., Amer, F. N., Reddy, R., & Alzghoul, B. N. (2026) · Lung · doi:10.1007/s00408-026-00939-2
“SUMMIT reported favourable heart-failure outcomes with tirzepatide and reductions in estimated blood volume, C-reactive protein, left ventricular mass, and paracardiac adipose tissue [25– 27 ].”
Okhovat, V., Lybeshari, K., Cubeddu, L. X., & Hale, G. M. (2026) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-026-00829-1
Obesity, incretin-based therapies, and cardiovascular disease in women
Salih, M., Sloots, Y. A. J., Hemels, M. E. W., Meems, L. M. G., Leening, M. J. G., & Ghossein‐Doha, C. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02084-0
“Additionally, studies with incretin-based therapies have demonstrated significant reduction in adverse cardiovascular events and death among patients with obesity or overweight and established CVD [14, 15].”
InfluentialLi, M. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1926629
“Among 731 patients with HFpEF and obesity, tirzepatide reduced the composite of cardiovascular death or worsening heart failure, with a hazard ratio of 0.62, and also improved health status and walking distance (16).”
InfluentialSegurança Cardiovascular da Tirzepatida- Uma Revisão Integrativa
Nascimento, E. N., Peres, A. C. F., Petrillo, B. A., Naves, B. P. P., Santos, G. S. E. O., da Silva, M. E. A., Peixoto, N. L. D. Á., & Oliveira, R. D. C. (2026) · Revista Master Ensino Pesquisa e Extensão · doi:10.47224/revistamaster.v11i21.859
Mizdrak, M., Batistic, D., & Mizdrak, I. (2026) · Medical Sciences · doi:10.3390/medsci14050577
Amaral, V. M. D., Souza, S. H. B. D., Campos, J. G. M., Ângelo, M. B., Carvalho, V. A. S., Clemente, J. O., Costa, J. A. B., & Splendor, M. C. (2026) · LUMEN ET VIRTUS · doi:10.56238/levv17n64-086
Majanović, S. K., Belančić, A., Gkrinia, E. M. M., Božek, T., Štimac, I., & Ciudin, A. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102141
HFpEF in Asia—Clinical Characterization and Therapeutic Strategies
Tromp, J., Teng, T. K., Tay, W. T., Chandramouli, C., Schiattarella, G. G., & Lam, C. S. P. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.08.009
Economic evaluations of antiobesity medications: A systematic literature review
Jurković, M., Fajkić, A., Faour, A. K., Momčilović, M., Turčić, P., & Belančić, A. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70825
Huang, Y., Li, P.-Y., Liu, K.-W., Li, P., Chen, S.-C., Chen, J., Meyerowitz‐Katz, G., Huang, J.-Y., & Su, P. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261490985
Rassam, F., Lopez, E. A., Sass, S., Srikulmontri, T., Isaacs, E., Malin, J. H., Wattanachayakul, P., & Afolabi-Brown, O. (2026) · Journal of Arrhythmia · doi:10.1002/joa3.70455
“Trials showed that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce mortality and improve cardiovascular outcomes in HFpEF [4].”
Weight management in cardiology practice: challenges and opportunities
Leening, M. J. G., Martens, F. M. A. C., & Hemels, M. E. W. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02075-1
Lucas, G. O. F. G., Baquetti, F. A. L., Harb, H. H., Carvalho, L. M. P., Piratelo, V. J., & Adamowski, E. D. V. (2026) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2026v8n9p1352-1370
Eighty Years After Vague: Advances in Understanding Ectopic Fat and Metabolic Dysfunction
Conte, C., Sumithran, P., le Roux, C. W., Miras, A. D., & Gaal, L. V. (2026) · Obesity Reviews · doi:10.1111/obr.70229
Advances in weight-loss-independent cardiovascular protective mechanisms of GLP-1 receptor agonists
Ma, J., Feng, X., Xu, W., & Lyu, J. (2026) · Peptides · doi:10.1016/j.peptides.2026.171519
AGONISTAS DUAIS DE GLP-1/GIP NO TRATAMENTO DA OBESIDADE E DAS DOENÇAS METABÓLICAS
Cabellino, L. F., de Sá, H. K. B., Hillesheim, V. D. S. F., RAPOSO, C. W. D. L. C., Crott, C. B., Santos, G. C., Tiago, J. C., Moreira, M. Z. F., Sismeiro, L. F. D. C., Torres, A. B., et al. (2026) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2026v8n9p1352-1371
Kazi, M. A. I., Mufarrih, S. M., Sirohi, A., Hasan, F., Sharma, A., Singh, S., Muganlinskaya, N. F., & Haq, N. (2026) · PLoS ONE · doi:10.1371/journal.pone.0358659
“The mechanisms underlying cardiovascular risk in IBD include cytokine-mediated endothelial dysfunction, platelet activation, increased arterial stiffness, and a pro-thrombotic state that persists even during clinical remission [11–13].”
Mayne, K. J., Lee, M. M. Y., Sattar, N. A., & Herrington, W. G. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107193
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
“…SUMMIT demonstrated that tirzepatide reduces the composite of cardiovascular death or worsening heart-failure events (HR 0.62, 95% CI 0.41 to 0.95) (75), with secondary analyses showing reductions in systolic blood pressure, estimated blood volume, C-reactive protein, and troponin T suggesting…”
InfluentialNICE chronic heart failure guideline update: implications for primary care
Jones, N. R., Lee, J., Goyder, C., Rayner, J. J., Gamble, J., Hobbs, F. D. R., & Taylor, C. J. (2026) · British Journal of General Practice · doi:10.3399/bjgp.2026.0319
Michos, E. D., Ambrosy, A. P., & Fonarow, G. C. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103280
Sun, X., Tang, X., Jin, M., Yuan, W., & Yuan, G. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1901876
Cardiorenal Syndrome: Pathophysiology, Management, and the Challenge of Therapeutic Inertia
Gembillo, G., Calabrese, V., Soraci, L., Cicero, L. L., Scapellato, M., Messina, R., Ricca, M. F., Stancanelli, M. R., Corsonello, A., & Santoro, D. (2026) · Medicina · doi:10.3390/medicina62101855
“Tirzepatide, a dual GIP/GLP-1 receptor agonist, lowered cardiovascular death or worsening HF in obesity-related HFpEF in the SUMMIT trial [66], and a dedicated kidney outcome trial of tirzepatide has yet to report.”
GLP-1 Based Therapies for Obesity in Older Adults: Current Evidence and Emerging Treatments
Pendrey, A., Sierra, J. A. R., Alvarez, F. A., Muñoz, Y. M. F., & Sevilla‐Martir, J. (2026) · Global Journal of Obesity Diabetes and Metabolic Syndrome · doi:10.17352/gjodms.000071
Alkhateeb, F. S. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02716-x
“In obesity-related HFpEF, further work should clarify the extent to which improvements are mediated by weight loss, reduced congestion, changes in paracardiac adipose tissue, cardiac remodeling, or other mechanisms [18, 19, 35 ].”
InfluentialNew-Onset Heart Failure in Patients with Obesity using Tirzepatide or SemaglutidePreprint
Al-Nusair, M., Haddad, T. A., Khurana, S., & Al‐Nusair, J. (2026) · medRxiv · doi:10.64898/2026.09.21.26363546
Efficacy and safety of tirzepatide in the treatment of obesity and obesity-associated comorbidities
Sakhnova, E. E., Gavrilova, N. A., Ostroumova, O. D., Кочетков, А. И., Telkova, S. S., & Moryakova, Y. S. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-324
贾, 秋. (2026) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2026.55326
Merolla, A., & Rovere, P. Q. (2026) · Cardiac failure review · doi:10.15420/cfr.2026.22
“36 Given the high expression of GIP receptors in epicardial adipocytes, dual agonism with tirzepatide may provide additional anti-inflammatory and cardiometabolic benefits beyond those achieved with GLP-1 receptor agonism alone.”
Influential
Metadata
- Authors
- Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., Hurt, K. C., Murakami, M., & Borlaug, B. A.
- Affiliations
- Cleveland Clinic (US)
- From Baylor University Medical Center, Dallas (M.P.); Imperial College, London (M.P.); RHJ Department of Veterans Affairs, Health System and Medical University of South Carolina, Charleston (M.R.Z., S.E.L.); the Cardiovascular Division, Department of Medicine, University of Virginia Health System, Charlottesville (C.M.K.); Flourish Research, Boca Raton, FL (S.J.B.); the Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland (V.M.); the Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China (J.G.); Eli Lilly, Indianapolis (G.J.W., Y.O., M.C.B., K.C.H., M.M.); and the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-01-30
- Volume
- 392
- Issue
- 5
- Pages
- 427-437
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404437149
- Semantic Scholar
- aeedfcfb5543cef26bd4f4576e1c5a59b4d2424f
- Cited by
- 1,009
- References
- 30
- Citations by year
- 2026: 496 · 2025: 494
- FWCI
- 303.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company (N/A)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, heart failure with preserved ejection fraction, obesity, GIP/GLP-1 receptor agonist, weight loss, cardiovascular mortality, worsening heart failure, Kansas City Cardiomyopathy Questionnaire, quality of life, body mass index, GLP-1 receptor agonists, GIP receptor agonist, cardiovascular outcomes, weight loss treatment, heart failure with reduced ejection fraction
- MeSH terms
- Tirzepatide, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Humans, Male, Middle Aged, Obesity, Quality of Life, Stroke Volume, Weight Loss, Body Mass Index, Treatment Outcome, Glucagon-Like Peptide 1, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.